

TABLES

S235	Table 1. Hierarchy of outcomes
S236	Table 2. Clinical questions and systematic review topics in PICOM format
S241	Table 3. Classification for quality and certainty of the evidence
S241	Table 4. GRADE system for grading quality of evidence
S242	Table 5. KDIGO nomenclature and description for grading of recommendations
S242	Table 6. Determinants of the strength of recommendation

FIGURES

S21	Figure 1. Updates to the KDIGO guideline format
S30	Figure 2. Considerations for a kidney biopsy in patients with proteinuria and/or glomerular hematuria
S31	Figure 3. Evaluation of kidney tissue
S91	Figure 4. Definition of “nephrotic syndrome,” “nephrotic-range proteinuria,” and “non-nephrotic-range proteinuria”
S32	Figure 5. Assessment of kidney function in glomerular disease
S94	Figure 6. Summary of supportive management of glomerular disease
S33	Figure 7. Edema management in NS
S34	Figure 8. Management of hypertension and proteinuria in glomerular disease
S98	Figure 9. Management of hypertension in glomerular disease
S35	Figure 10. Management of hyperlipidemia in glomerular disease
S36	Figure 11. Anticoagulation in NS
S37	Figure 12. Anticoagulant dosing considerations in patients with NS
S38	Figure 13. Prophylactic anticoagulation in adults with GN/nephrotic syndrome
S107	Figure 14. Screening/prophylaxis for all patients with glomerular disease on immunosuppression
S39	Figure 15. Minimization of immunosuppression-related adverse effects
S40	Figure 16. Dietary suggestions in glomerular disease
S111	Figure 17. Coordinated care of pregnant patients with glomerular disease
S112	Figure 18. Contraception in women with glomerular disease
S113	Figure 19. An overview of the impact of glomerular disease in women
S116	Figure 20. The data elements included in the International IgAN Prediction Tool
S42	Figure 21. Initial assessment and management of the patient with IgAN
S120	Figure 22. Glucocorticoid regimens used in clinical trials of IgAN where there was uniform use of renin-angiotensin system (RAS) inhibition
S44	Figure 23. Situations when glucocorticoids should be avoided, or administered with great caution
S45	Figure 24. Management of patients with IgAN who remain at high risk for progression after maximal supportive care
S46	Figure 25. Other pharmacologic therapies evaluated in IgAN
S47	Figure 26. Regional use of tonsillectomy as a treatment for IgAN
S128	Figure 27. Guidance for the use and interpretation of the anti-PLA2R antibody assay in patients with known anti-PLA2R-associated MN
S129	Figure 28. When to consider a kidney biopsy in a patient who is anti-PLA2R antibody-positive
S50	Figure 29. Evaluation of patients with MN for associated conditions
S51	Figure 30. Clinical criteria for assessing risk of progressive loss of kidney function
S52	Figure 31. Risk-based treatment of MN
S132	Figure 32. Commonly used treatment regimens for patients with MN
S53	Figure 33. Immunologic monitoring in MN after start of therapy
S53	Figure 34. Management of initial relapse after therapy in MN
S54	Figure 35. Management of resistant disease in MN